DoD/BioPort Seeking Anthrax Vaccine Change To Safer Five-Dose IM Regimen

Studies supporting approval of a five-dose intramuscular regimen for the anthrax vaccine could be available in two years, according to BioPort Corporation, which is conducting the studies on behalf of the Department of Defense.